个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Li, J.[1,4] * ; Pu, X.[2] ; Zhang, B.[3] ; Zhang, J.[4] ; Mok, T. S.[5] ; Nakagawa, K.[6] ; Rosell, R.[7] ; Cheng, Y.[8] ; Zhou, X.[9] ; Migliorino, M. R.[10] ; Niho, S.[11] ; Lee, K. H.[12] ; Corral, J.[13] ; Pluzanski, A.[14] ; Li, J.[15] ; Linke, R.[16] ; Pan, F.[17] ; Tang, Y.[18] ; Tan, W.[19] ; Wu, L.[20] ;
机构： [1]Sichuan Cancer Hospital, Chengdu, Sichuan/CN [2]Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha/CN [3]Shanghai Chest Hospital, Jiao Tong University, Shanghai/CN [4]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN [5]State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong/CN [6]Kindai University, Osaka/JP [7]Dr. Rosell Oncology Institute and Quirón-Dexeus University Institute, Barcelona/ES [8]Jilin Cancer Hospital, Changchun/CN [9]First Affiliated Hospital of Third Military Medical University, Chongqing/CN [10]Responsabile UOSD di Pneumologia ad indirizzo Oncologico and Azienda Ospedaliera San Camillo-Forlanini, Roma/IT [11]National Cancer Center Hospital East, Thoracic Oncology, Kashiwa, Chiba/JP [12]Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju/KR [13]Clinica Universidad de Navarra, Madrid/ES [14]The Maria Sklodowska-Curie Memorial Cancer Centre and Insititute of Oncology, Warsaw/PL [15]SFJ Pharmaceuticals, Pleasanton/CA/USA [16]Pfizer, Beijing/CN [17]Pfizer, San Diego/CA/USA [18]Department of Thoracic Medical Oncology, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/CN
出处：
ISSN：

关键词： non-small cell lung cancer dacomitinib skin disorders

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2022]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Sichuan Cancer Hospital, Chengdu, Sichuan/CN [4]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN
推荐引用方式(GB/T 7714)：
Li J.,Pu X.,Zhang B.,et al.Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study[J].JOURNAL OF THORACIC ONCOLOGY.2022,17(9):S480-S482.
APA：
Li, J.,Pu, X.,Zhang, B.,Zhang, J.,Mok, T. S....&Wu, L..(2022).Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study.JOURNAL OF THORACIC ONCOLOGY,17,(9)
MLA：
Li, J.,et al."Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study".JOURNAL OF THORACIC ONCOLOGY 17..9(2022):S480-S482

相关文献

[1]Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050 [2]Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials [3]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [4]KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review [5]Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer [6]非小细胞肺癌小细胞转化的分子特征及治疗进展 [7]Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)(Open Access) [8]RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non-small cell lung cancer cells [9]Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression [10]Treatment of Lung Carcinosarcoma and Other Rare Histologic Subtypes of Non-small Cell Lung Cancer

资源点击量：54033 今日访问量：0 总访问量：4614 更新日期：2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号